Merck (MRK) Phase 3 TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints
Key takeaways
- Merck (MRK) Phase 3 Tro Fuse-005 Trial for Endometrial Cancer Meets Primary Endpoints Maham Fatima Sat, May 23, 2026 at 7:01 PM GMT+7 2 min read MRK 6990.HK Merck & Co.
- The trial also achieved its key secondary endpoint of objective response rate, maintaining a safety profile consistent with prior sac-TMT studies with no new safety signals.
- This milestone represents the first positive Phase 3 data from Merck & Co.
Merck (MRK) Phase 3 Tro Fuse-005 Trial for Endometrial Cancer Meets Primary Endpoints Maham Fatima Sat, May 23, 2026 at 7:01 PM GMT+7 2 min read MRK 6990.HK Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal Phase 3 Tro Fuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT) met its dual primary endpoints of overall survival/OS and progression-free survival/PFS in patients with advanced or recurrent endometrial cancer. The investigational TROP2-directed antibody-drug conjugate, developed in collaboration with Kelun-Biotech, is the first global Phase 3 trial to show statistically significant improvements in OS and PFS compared to standard chemotherapy in this patient population.
The pre-specified interim analysis demonstrated clinically meaningful efficacy against the physician’s choice of treatment (doxorubicin or paclitaxel) for individuals whose disease progressed following platinum-based chemotherapy and anti-PD-1/L1 immunotherapy. The trial also achieved its key secondary endpoint of objective response rate, maintaining a safety profile consistent with prior sac-TMT studies with no new safety signals.
This milestone represents the first positive Phase 3 data from Merck & Co. Inc.’s (NYSE:MRK) expansive TroFuse clinical development program. The ongoing program encompasses 17 global Phase 3 trials across multiple tumor types (including bladder, breast, cervical, and non-small cell lung cancers) and aims to establish the therapy as a cornerstone treatment in both early and late-stage disease settings.